日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Feasibility and efficacy of addition of individualized-dose lenalidomide to chlorambucil and rituximab as first-line treatment in elderly and FCR-unfit patients with advanced chronic lymphocytic leukemia

在老年和不适合接受FCR方案治疗的晚期慢性淋巴细胞白血病患者中,一线治疗方案中加入个体化剂量的来那度胺联合苯丁酸氮芥和利妥昔单抗的可行性和疗效

Kater, Arnon P; van Oers, Marinus H J; van Norden, Yvette; van der Straten, Lina; Driessen, Julia; Posthuma, Ward F M; Schipperus, Martin; Chamuleau, Martine E D; Nijland, Marcel; Doorduijn, Jeanette K; Van Gelder, Michel; Hoogendoorn, Mels; De Croon, Francien; Wittebol, Shulamiet; Kerst, J Martijn; Marijt, Erik W A; Raymakers, Reinier A P; Schaafsma, Martijn R; Dobber, Johan A; Kersting, Sabina; Levin, Mark-David

Obinutuzumab pretreatment abrogates tumor lysis risk while maintaining undetectable MRD for venetoclax + obinutuzumab in CLL

在慢性淋巴细胞白血病(CLL)患者中,奥妥珠单抗预处理可消除肿瘤溶解风险,同时维持维奈托克联合奥妥珠单抗治疗方案中微小残留病灶(MRD)检测不到。

Kater, Arnon P; Kersting, Sabina; van Norden, Yvette; Dubois, Julie; Dobber, Johan A; Mellink, Clemens H; Evers, Ludo M; Croon-de Boer, Fransien; Schreurs, John; van der Spek, Ellen; Visser, Hein; Idink, Cecile; Wittebol, Shulamiet; Hoogendoorn, Mels; Tonino, Sanne H; Mobasher, Mehrdad; Levin, Mark-David

Soluble CD52 is an indicator of disease activity in chronic lymphocytic leukemia

可溶性CD52是慢性淋巴细胞白血病疾病活动的指标。

Vojdeman, Fie J; Herman, Sarah E M; Kirkby, Nikolai; Wiestner, Adrian; van T' Veer, Mars B; Tjønnfjord, Geir E; Itälä-Remes, Maija A; Kimby, Eva; Farooqui, Mohammed Z; Polliack, Aaron; Wu, Ka Lung; Doorduijn, Jeanette K; Alemayehu, Wendimagegn G; Wittebol, Shulamiet; Kozak, Tomas; Walewski, Jan; Abrahamse-Testroote, Martine C J; van Oers, Marinus H J; Geisler, Christian H; Niemann, Carsten U

Phase I/II trial of weekly bortezomib with lenalidomide and dexamethasone in first relapse or primary refractory myeloma

一项针对首次复发或原发性难治性多发性骨髓瘤患者的I/II期临床试验,评估每周一次硼替佐米联合来那度胺和地塞米松的疗效。

Broijl, Annemiek; Kersten, Marie-José; Alemayehu, Wendimagegn Ghidey; Levin, Mark-David; de Weerdt, Okke; Vellenga, Edo; Meijer, Ellen; Wittebol, Shulamit; Tanis, Bea C; Cornelisse, Petra B; Stevens-Kroef, Marian; Bos, Gerard M J; Wijermans, Pierre W; Lokhorst, Henk; Sonneveld, Pieter

Multi-center randomized open label phase II trial on three rituximab dosing schemes in immune thrombocytopenia patients

一项针对免疫性血小板减少症患者的多中心随机开放标签II期临床试验,研究了三种利妥昔单抗给药方案。

Zwaginga, Jaap J; van der Holt, Bronno; Te Boekhorst, Peter A; Biemond, Bart J; Levin, Mark-David; van der Griend, René; Brand, Anneke; Zweegman, Sonja; Pruijt, Hans F M; Novotny, Vera M J; Vreugdenhil, Art; de Groot, Marco R; de Weerdt, Okke; van Pampus, Elisabeth C M; van Maanen-Lamme, Tanja M; Wittebol, Shulamiet; Schipperus, Martin R; Silbermann, Matthijs H; Huijgens, Peter C; Luten, Marleen; Hollestein, Rene; Brakenhoff, Jan A C; Schrama, Jolanda G; Valster, Fransje A A; Velders, Gerjo A; Koene, Harry R

Reduced relapse rate in upfront tandem autologous/reduced-intensity allogeneic transplantation in multiple myeloma only results in borderline non-significant prolongation of progression-free but not overall survival

在多发性骨髓瘤中,初始自体/减低强度异基因联合移植可降低复发率,但仅能略微延长无进展生存期,而不能延长总生存期。

Lokhorst, Henk M; van der Holt, Bronno; Cornelissen, Jan J; Kersten, Marie José; van Oers, Marinus; Raymakers, Reinier; Minnema, Monique C; Zweegman, Sonja; Bos, Gerard; Schaap, Nicolaas; Wittebol, Shulamiet; de Weerdt, Okke; Ammerlaan, Rianne; Sonneveld, Pieter

Quality of life of patients with chronic lymphocytic leukaemia in the Netherlands: results of a longitudinal multicentre study

荷兰慢性淋巴细胞白血病患者的生活质量:一项纵向多中心研究的结果

Holtzer-Goor, K M; Schaafsma, M R; Joosten, P; Posthuma, E F M; Wittebol, S; Huijgens, P C; Mattijssen, E J M; Vreugdenhil, G; Visser, H; Peters, W G; Erjavec, Z; Wijermans, P W; Daenen, S M G J; van der Hem, K G; van Oers, M H J; Uyl-de Groot, C A

Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial

在自体干细胞移植前后使用硼替佐米可克服新诊断多发性骨髓瘤患者肾功能损害的不良预后影响:HOVON-65/GMMG-HD4 试验的亚组分析

Scheid, Christof; Sonneveld, Pieter; Schmidt-Wolf, Ingo G H; van der Holt, Bronno; el Jarari, Laila; Bertsch, Uta; Salwender, Hans; Zweegman, Sonja; Blau, Igor Wolfgang; Vellenga, Edo; Weisel, Katja; Pfreundschuh, Michael; Jie, Kon-Siong; Neben, Kai; van de Velde, Helgi; Duehrsen, Ulrich; Schaafsma, M Ron; Lindemann, Walter; Kersten, Marie José; Peter, Norma; Hänel, Mathias; Croockewit, Sandra; Martin, Hans; Wittebol, Shulamiet; Bos, Gerard Mj; van Marwijk-Kooy, Marinus; Wijermans, Pierre; Goldschmidt, Hartmut; Lokhorst, Henk M

The therapeutic human CD38 antibody daratumumab improves the anti-myeloma effect of newly emerging multi-drug therapies

治疗性人源CD38抗体daratumumab可增强新型多药联合疗法的抗骨髓瘤疗效。

van der Veer, M S; de Weers, M; van Kessel, B; Bakker, J M; Wittebol, S; Parren, P W H I; Lokhorst, H M; Mutis, T

Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab

迈向多发性骨髓瘤的有效免疫治疗:来那度胺联合人CD38单克隆抗体达雷妥尤单抗可增强对骨髓瘤细胞的清除。

van der Veer, Michael S; de Weers, Michel; van Kessel, Berris; Bakker, Joost M; Wittebol, Shulamiet; Parren, Paul W H I; Lokhorst, Henk M; Mutis, Tuna